D. Western Therapeutics Institute, Inc.

Summary

D. Western Therapeutics Institute, Inc., a biotechnology company, focuses on developing drugs to serve patients worldwide. The company offers GLANATEC, an ophthalmic solution for the treatment of glaucoma/ocular hypertension; and DW-1002, an ophthalmic surgical adjuvant for cataract surgeries, and ILM staining and peeling. It is also developing H-1337, a multikinase inhibitor that has completed Phase I/IIa clinical trials for the treatment of glaucoma/ocular hypertension; K-134, an antiplatelet agent, which has completed Phase IIb trials to treat arteriosclerosis obliterans; DW-1001, an ophthalmic treatment agent in nonclinical studies; and DW-5LBT, a lidocaine patch for neuropathic pain after shingles. The company was founded in 1999 and is headquartered in Nagoya, Japan.